- Home
- CVBF vs IBRX Comparison
CVBF vs IBRX Comparison
Compare CVBF & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVBF
- IBRX
- Stock Information
- Founded
- CVBF 1974
- IBRX 2014
- Country
- CVBF United States
- IBRX United States
- Employees
- CVBF N/A
- IBRX N/A
- Industry
- CVBF Major Banks
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CVBF Finance
- IBRX Health Care
- Exchange
- CVBF Nasdaq
- IBRX Nasdaq
- Market Cap
- CVBF 2.7B
- IBRX 2.3B
- IPO Year
- CVBF N/A
- IBRX N/A
- Fundamental
- Price
- CVBF $18.84
- IBRX $2.09
- Analyst Decision
- CVBF Buy
- IBRX Strong Buy
- Analyst Count
- CVBF 3
- IBRX 6
- Target Price
- CVBF $24.33
- IBRX $9.83
- AVG Volume (30 Days)
- CVBF 758.0K
- IBRX 8.7M
- Earning Date
- CVBF 10-22-2025
- IBRX 11-04-2025
- Dividend Yield
- CVBF 4.24%
- IBRX N/A
- EPS Growth
- CVBF 4.23
- IBRX N/A
- EPS
- CVBF 1.48
- IBRX N/A
- Revenue
- CVBF $509,488,000.00
- IBRX $82,555,000.00
- Revenue This Year
- CVBF N/A
- IBRX $629.94
- Revenue Next Year
- CVBF $3.93
- IBRX $109.91
- P/E Ratio
- CVBF $12.75
- IBRX N/A
- Revenue Growth
- CVBF N/A
- IBRX 1025.95
- 52 Week Low
- CVBF $16.01
- IBRX $1.83
- 52 Week High
- CVBF $24.58
- IBRX $5.43
- Technical
- Relative Strength Index (RSI)
- CVBF 51.51
- IBRX 39.04
- Support Level
- CVBF $18.55
- IBRX $2.00
- Resistance Level
- CVBF $18.97
- IBRX $2.22
- Average True Range (ATR)
- CVBF 0.41
- IBRX 0.13
- MACD
- CVBF 0.05
- IBRX -0.02
- Stochastic Oscillator
- CVBF 62.13
- IBRX 20.42
About CVBF CVB Financial Corporation
CVB Financial Corp is the holding company for Citizens Business Bank. Citizens Business Bank offers banking, lending, and investing services. It provides a full complement of lending products, including commercial, agribusiness, consumer, SBA, real estate, and construction loans, as well as equipment and vehicle leasing. Commercial products include lines of credit and other working capital financing, accounts receivable lending and letters of credit.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.